Related Experiment Video
Updated: May 6, 2026
Comparative Lesions Analysis Through a Targeted Sequencing Approach
Published on: November 5, 2019
Genomic analyses identify molecular subtypes of pancreatic cancer
Peter Bailey1,2, David K Chang2,3,4,5, Katia Nones1,6
1Queensland Centre for Medical Genomics, Institute for Molecular Bioscience, The University of Queensland, St Lucia, Brisbane, Queensland 4072, Australia.
Abstract:
Integrated genomic analysis of 456 pancreatic ductal adenocarcinomas identified 32 recurrently mutated genes that aggregate into 10 pathways: KRAS, TGF-β, WNT, NOTCH, ROBO/SLIT signalling, G1/S transition, SWI-SNF, chromatin modification, DNA repair and RNA processing. Expression analysis defined 4 subtypes: (1) squamous; (2) pancreatic progenitor; (3) immunogenic; and (4) aberrantly differentiated endocrine exocrine (ADEX) that correlate with histopathological characteristics. Squamous tumours are enriched for TP53 and KDM6A mutations, upregulation of the TP63∆N transcriptional network, hypermethylation of pancreatic endodermal cell-fate determining genes and have a poor prognosis. Pancreatic progenitor tumours preferentially express genes involved in early pancreatic development (FOXA2/3, PDX1 and MNX1). ADEX tumours displayed upregulation of genes that regulate networks involved in KRAS activation, exocrine (NR5A2 and RBPJL), and endocrine differentiation (NEUROD1 and NKX2-2). Immunogenic tumours contained upregulated immune networks including pathways involved in acquired immune suppression. These data infer differences in the molecular evolution of pancreatic cancer subtypes and identify opportunities for therapeutic development.
Insights
This study analyzed 456 pancreatic ductal adenocarcinomas, revealing 4 distinct molecular subtypes with unique genetic mutations and pathway activations. These findings offer new therapeutic targets for pancreatic cancer treatment.
Area of Science:
- Oncology
- Genomics
- Molecular Biology
Background:
- Pancreatic ductal adenocarcinoma (PDAC) is a lethal malignancy with limited therapeutic options.
- Understanding the molecular heterogeneity of PDAC is crucial for developing targeted therapies.
Purpose of the Study:
- To perform an integrated genomic and expression analysis of a large cohort of PDAC.
- To identify molecular subtypes and their associated genetic alterations and pathway dysregulations.
- To explore potential therapeutic avenues based on subtype-specific molecular profiles.
Main Methods:
- Integrated genomic analysis of 456 pancreatic ductal adenocarcinomas.
- Identification of recurrently mutated genes and pathway aggregation.
- Gene expression analysis to define molecular subtypes.
- Correlation of molecular subtypes with histopathological characteristics and clinical outcomes.
Main Results:
- Identified 32 recurrently mutated genes across 10 key pathways (e.g., KRAS, TGF-β, SWI-SNF).
- Defined 4 distinct molecular subtypes: squamous, pancreatic progenitor, immunogenic, and aberrantly differentiated endocrine exocrine (ADEX).
- Squamous subtype associated with TP53 mutations, poor prognosis, and hypermethylation; pancreatic progenitor with early development genes; ADEX with KRAS activation and differentiation pathways; immunogenic with immune suppression pathways.
Conclusions:
- Pancreatic cancer exhibits significant molecular heterogeneity, with distinct subtypes arising from different evolutionary trajectories.
- The identified subtypes present unique molecular vulnerabilities that can be exploited for targeted therapeutic development.
- This comprehensive analysis provides a roadmap for precision medicine in pancreatic cancer.
